|
Post by careful2invest on Jan 30, 2017 23:18:21 GMT -5
God knows careful, I'm with ya! The last really good news was approval and that was short lived. Think about it....that was June 28th 2014 and here we are in 2017. I guess we should be thankful that we are still here awaiting the riches. Just give the damn PPS a lift off the bottom....PLEASE! I get that! And that was on my birthday. I remember it well! And that too was ill managed! But, Like I've said before, It's better to be too early on purchasing a stock than too late. Right? I keep telling myself that... How many stocks have you heard about after the fact? After they blow up?Thinking...If I had only pulled the trigger on that one...I can think of a handfull over the years. Let's hope the commercial potential of AFREZZA is recognized to the fullest and this turns out to be an investment of a lifetime! Because when I purchased my first shares of MNKD, I felt that this is one of those (very few) stocks that give that once in a lifetime return. One thing's for sure, good or bad, the waiting is close to being over. Sink or swim. AFREZZA works well. That cat is out of the bag, and imho, never to be smothered again. Hopefully, we'll be very happy with our current management and their most recent accomplishments on Wednesday! God knows that we longs deserve it! GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 30, 2017 18:04:27 GMT -5
If the news is really good I'll be totally lost. If that is the case, I welcome being "lost" with good news. I'll find my way... Better than the seven years spent in the dark with basically no news, let alone good news at all! I would love to find myself basking in an "embarrassment of riches" on Wednesday! Finally watching this "epic" turnaround come to fruition. I'm not expecting to see the pinnacle of this company's potential on Wednesday, but an announcement of a healthy step in that direction does seem to be accessible at this point! Let's hope! GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 28, 2017 16:58:44 GMT -5
What ever happened to our once hyped oncology programs? They seemed to have vanished from the face of the earth. Are they still somewhere on planet earth?! You know, the deals with Tolero & Colby? How about the inhaled pain medicine with Torrey Pine that Al Mann said was awesome? I was once hyped up about the potential of that one! If it was as good as advertised the market would be incredibly massive for that product. Of course the Receptor Life Science thing about inhaled weed has been beaten to death, but we still know zip, zilch, nada about that whole partnership and products under development. They did also steal Andrea Leone-Bay, who was presumably the top scientist in our entire organization, so that is a bit troubling. I'm sure I'm forgetting others, I've been in this story for many years and our "pipeline" has changed several times thru the years. Please chime in with additional points of interest I should have included. Why to these partnerships seemingly never amount to anything, never advance, never get heard from again, and vanish off the face of the earth like it never happened? Since we are having a management conference for the sole purpose of updating shareholders and the market, how about you guys (Management) shed some light on EVERYTHING above that I just mentioned?! Hopefully, the above questions, along with many others will be answered on Wednesday. Even if the news is not absolutely over the top, hopefully it will be substantial and the beginning of something very substantial. GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 26, 2017 23:17:59 GMT -5
There is simply no good reason to delay the sharing of any good news. Those six words again... "It just does not make sense"
|
|
|
Post by careful2invest on Jan 25, 2017 12:08:38 GMT -5
I hate to beat this drum to death and maybe I am speaking mainly through frustration on my part as opposed to analytically thinking before I speak? However, the job of a good hype man, such as Flava Flav of Public Enemy, is to get the crowd energized....get them interested in the music.....ultimately selling the brand, making people feel good about the group.
MNKD needs someone like a Flava Flav! Matt and Mike, you guys need to get someone to post, to talk, to inform, to brag, to sale the product. Come on, normal A1C's; no needles; create a great depiction of that, put it on your web page. Brag about it, brag about throwing the needles away and trust me it will catch on. Brag about the sales the reps, brag about he pending deals, label changes, etc. Do not be scared about it falling through because trust me....we are getting tired of the future promises anyway. One more thing, say something on the website and stop waiting for conferences. Let us follow the direction of the company....please. I agree that there needs to be more of a prominent public voice promoting MNKD. BUT Flavor flav?? His ship has sailed. We can certainly up the ante from him! I dont think that Damon Dash is the best face for AFREZZA either, but Flavor flav definitely is going the wrong direction. There are many famous people with Diabetes from which to choose. Having more than a few on board would start the wave. One thing I know for certain is that MNKD needs to hire a professional advertising promoter to effectively lay out the launch strategy of AFREZZA and TECHNOSPHERE, if they have not already. While all of our ideas make for good conversation, unless you are in the advertising industry, we should leave it to the pros. Hiring the right (competent) people to effectively lay out an advertising plan makes the most sense to me. Hire the correct tradesman for the trade. Simple as that. It needs to be cutting edge and on point! Nothing less than perfection. After billions of dollars have already been spent to get us this far, MNKD cannot afford to lose the war! We'll see what MNKD comes up with. I have not understood why after two plus years after FDA approval, many Endo's and GP's still have never heard of AFREZZA or TECHNOSPHERE! It just does not make sense! GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 23, 2017 22:53:41 GMT -5
No I am not a Mannkind employee. And no, it is not strange to expect the company to follow up on a lead that was handed to them. I gave them the contact to the executive administrator who had instructions from the doctors in the diabetes department to set up the presentation once Mannkind made contact. They never did. What more can one ask for, especially as they have to train their new sales staff on how to get endos interested... Maybe MNKD management expects that the endos should get trained on how to get MNKD interested... LOL A MNKD director was involved when I was making the arrangements (you should have asked before calling me rude...) as well as another Afrezza trainer who is working hand-in-glove with MNKD. This person was fantastic and so helpful and interested, however after the meeting was arranged, this director dropped off the face of the Earth and Mike or Matt never bothered to reply, at least to provide me with their email inviting details. Prior to me making that arrangement, the department itself has a conference in the hospital to which all the major diabetes drug manufacturers were invited, Mannkind included. I was told that MNKD initially accepted, only to call one day before the meeting saying that they could not attend. Everyone else attended, as they should have... If what you have written is true, first off, It makes absolutely no sense for MNKD to not follow up and participate in everything possible to gain market exposure and market acceptance to advance the sales of AFREZZA. No stone should be left unturned. Hopefully, someone made a mistake in conveying exactly how it all went down, and Matt and Mike did not drop the ball. Please follow up if you hear differently. I have to mention... How many times have you said these six words to yourself or to others when it comes to the "supposed marketing" of AFREZZA... "It just does not make sense"! Over the seven years that I have owned this stock, it has happened way too often. It Just does not make sense! Even going all of the way back to FDA approval, MNKD's approach just has not made good business sense. I have always given them the benefit of the doubt thinking that they are professionals, they certainly have to know what they are doing. Right? Maybe not so... Granted, Sanofi screwed us and Mike and Matt have done a lot in reasonably short time, but we are nowhere near where we should be, given that we have a revolutionary, FDA approved treatment for Diabetes, second only to a healthy human pancreas when it comes to BG control in the treatment of Diabetes. The clock is ticking...Potential delisting, limited cash, etc. I keep hoping that they honestly have a solid plan that will explain their decision making processes to date. Anything short of that just does not make sense! AFREZZA has made it this far already! It works! And it works very well! AFREZZA is REVOLUTIONARY! Add to that, Alfred Manns Legacy, Al's own personal investment, etc. etc They cannot possibly be that inept, right??? And here we are again and still... speculating about what's going to happen to MNKD and our investment. I still remain hopeful, because, 1) I believe in the potential of AFREZZA, and 2) because my original six figure investment in MNKD has dropped too low to sell at this point. Just gonna ride it out...Total loss or Home run? Time will tell! Come on Mike and Matt!! GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 16, 2017 22:31:52 GMT -5
What does Damon Dash have to do with Vdex? Did he buy Vdex from Bill? Did I miss a press release? If Dash is planning to open those 100+ clinics, I am all for it. Probably nothing. But since you mention Damon Dash, IMHO, I believe that we (MNKD) can find a better front man to represent the brand and be the face of AFREZZA. GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 13, 2017 20:20:52 GMT -5
Agree with almost all of the above, although the 120 million is not "new funding." In any event, I was especially encouraged by the news about the reality TV show...a smart way to deliver a targeted message. MY GUESS IS THIS IS THE TV REALITY SHOW THAT MNKD WILL BE SPONSORING. t.co/CHB4yni8HV?ssr=trueDated March of 2014.
|
|
|
Post by careful2invest on Jan 13, 2017 20:06:15 GMT -5
The Need for Faster Insulin Problem Solved? Douglas B. Muchmore, MD First Published January 1, 2017 review-article PDF download for The Need for Faster Insulin Article Information Full Access Abstract Considerable progress in treatment of diabetes has been made in the nearly 100 years following the discovery of insulin, and advances in insulin therapy have improved convenience, quality of life, overall glycemic control (A1C), and risk of hypoglycemia. An unmet need remains for a mealtime insulin that can faithfully reproduce the metabolic profile that ensues following meal ingestion in healthy persons. A number of “ultra-fast” insulin programs have been initiated, and Afrezza® (insulin human; Inhalation Powder, MannKind Corporation, Danbury, CT) stands as the first such product to be approved by the US FDA. Afrezza is unique as an “ultra-ultra” fast insulin, faster than any other entrant except IV insulin. The benefits and limitations of the Afrezza profile are discussed in this article. analysis.http://journals.sagepub.com/doi/abs/10.1177/1932296816677577 AND journals.sagepub.com/doi/pdf/10.1177/1932296816677577 Another positive read about AFREZZA! We need more of this! GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 10, 2017 19:21:18 GMT -5
This at least gets the word out. I am in corporate sales. I am in all the major corporations in the NJ,NY,PA, CT market. Pepsi, ATT, Exxon, Aetna, Pfizer, Johnson and Johnson, Mondalez,Merck, Becton Dickinson, to name a few. I have been doing this for 27 years and speak with many people daily. I speak of Afrezza every day. I have yet to meet a single person who has ever heard of it. Many are interested. They are diabetic or have a parent, spouse, or child who is. My reason for explaining this is to make a point that of the literally thousands of people I have spoken with in the past several years, have never heard anything about it. A news report certainly raises interest, and most observers know someone who suffers from this horrible disease. The young man in the ad states that he doesn't feel like a diabetic anymore! I have not mentioned AFREZZA to thousands of people, but I have spoken to many about AFREZZA, and I too, have never met anyone that I mentioned AFREZZA to that had ever heard of it. Diabetics and non diabetics alike. MNKD desperately has to do something about that! Hopefully they start at Thursdays conference! GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 10, 2017 18:59:27 GMT -5
Afrezza has been on the local news acrosss the country several times in the past but it did not seem to affect the new rx subscription that much. It's still in the low 200's. MNKD needs new marketing strategies. Hopefully we receive some positive news on Thursday about their new strategy for AFREZZA and TECHNOSPHERE! It is time! GLTA TRUE LONGS!
|
|
|
Post by careful2invest on Jan 9, 2017 19:44:05 GMT -5
No problem. I'll be right back. I'll give you a 9.99 on the dive...The splash was a little too big for a perfect 10.
|
|
|
Post by careful2invest on Jan 6, 2017 12:52:11 GMT -5
Heads up,,,, Andrea is no longer scheduled to speak on Friday 2:00-2:30..... it now says TBD in that time slot. She has cancelled every time. I had a feeling she would cancel this time as well.. That stinks I was really looking forward to hearing her speak She has cancelled every time?? Literally? Do you think there is any logical explanation of her registering her name for these conferences and not following through? Or is it left as yet another "mystery" to unfold without explanation?
|
|
|
Post by careful2invest on Jan 5, 2017 17:23:38 GMT -5
Mine too but I have NO fear that payday is coming. MNKD's approach to marketing Afrezza has been practically speaking, non-existent. MNKD is keeping Afrezza on life support until their master plan elements all come together and I believe we are very, very close to that reality. I sure the hell hope it's this qtr. If a deal were to happen at $10 billion, Is there any way of calculating what a price of $10 billion would do to the pps? Educated estimates anyone?
|
|
|
Post by careful2invest on Jan 4, 2017 12:13:07 GMT -5
MannKind Announces Key Addition to Its Executive Management Ranks VALENCIA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Stuart A. Tross, Ph.D., has joined the company as its Chief People Officer, with responsibilities for Human Resources, Information Technology and West Coast Facilities. Dr. Tross will be integral in accelerating the company's development into a world-class, global biopharmaceutical company centered on the value of its human capital. He will be reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKind's executive leadership team. Dr. Tross joins MannKind with several decades of leadership experience in the life sciences industry. From 2006 to 2016 he served in roles of increasing responsibility at Amgen, the last three years as Senior Vice President and Chief Human Resources Officer responsible for Human Resources and Security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb, the last three years as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organization Psychology from the Georgia Institute of Technology. "To welcome Stuart to our executive management team, with his extensive biopharmaceutical background, is both timely and opportunistic. The addition of his wide-ranging experience will be transformational at MannKind," said Mr. Pfeffer. "Stuart's experience will not only facilitate a quick and efficient expansion of our Afrezza launch capability, but he will be instrumental in building an organization to accommodate other strategic initiatives, such as product development and global expansion." Dr. Tross commented, "I am excited to join the MannKind team during this time of rapid transformation. Afrezza is an innovative product in an area of unmet patient need with significant growth potential, and there are a number of additional growth opportunities in the pipeline. I look forward to contributing to MannKind's future." About MannKind Corporation MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the commercial potential of Afrezza. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to generate significant product sales for MannKind, difficulties or delays in obtaining regulatory feedback or completing and analyzing the results of clinical studies, MannKind's ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2015 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. Well, Dr. Stuart Tross has quite an impressive resume! And typically, you do not quit a 10 year position, no matter the circumstances, to join a dead end company because the "people are nicer to work with" as someone stated! Dead end is dead end! MNKD is up and coming! Finally!! My favorite parts in these paragraphs below are where they use words like "quick and efficient expansion of AFREZZA launch", "global expansion" and "rapid transformation" Cut and pasted... "To welcome Stuart to our executive management team, with his extensive biopharmaceutical background, is both timely and opportunistic. The addition of his wide-ranging experience will be transformational at MannKind," said Mr. Pfeffer. "Stuart's experience will not only facilitate a quick and efficient expansion of our Afrezza launch capability, but he will be instrumental in building an organization to accommodate other strategic initiatives, such as product development and global expansion." Dr. Tross commented, "I am excited to join the MannKind team during this time of rapid transformation. Afrezza is an innovative product in an area of unmet patient need with significant growth potential, and there are a number of additional growth opportunities in the pipeline. I look forward to contributing to MannKind's future." Things are about to get better! GLTA TRUE LONGS!
|
|